Trials / Terminated
TerminatedNCT03963973
A 28 Day Parallel Group Study to Assess the Effects of RDN-929
A Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetic (PK) Profile of Multiple Oral Doses of RDN-929 in Healthy Older Adults
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Alkermes, Inc. · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
Eligibility will be assessed during a screening period of up to 4 weeks. Subjects will take study medication once daily up to and including Day 28. Safety, tolerability and PK will be measured at each visit.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RDN-929 oral capsule | low, medium and high dose |
| DRUG | Placebo oral capsule | matching placebo dose |
Timeline
- Start date
- 2019-05-16
- Primary completion
- 2020-01-22
- Completion
- 2020-01-22
- First posted
- 2019-05-28
- Last updated
- 2020-02-20
Locations
2 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT03963973. Inclusion in this directory is not an endorsement.